Adrenal Hyperplasia, Congenital
11
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia
Questionnaire Study to Assess the Outcomes of the Management of Congenital Adrenal Hyperplasia Individuals
LC-MS / MS Adrenal Steroids Assayed on Dried Blot Spot for the Congenital Adrenal Hyperplasia Neonatal Screening (SPECTROSPOT)
Growth Hormone (GH) in Congenital Adrenal Hyperplasia
Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.
Research Study for Children With Salt Wasting Congenital Adrenal Hyperplasia
Clinical Evaluation of NeoPlex4 Assay and NeoPlex System
Dexamethasone Treatment of Congenital Adrenal Hyperplasia
Role of the Protein Osteoprotegerin in the Bone Health of Women With Congenital Adrenal Hyperplasia
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers